Women account for a large proportion of patients treated with transcatheter aortic valve replacement, yet there remain conflicting reports about the effect of sex on outcomes. Moreover, the sex-specific prevalence and prognostic impact of frailty has not been systematically studied in the context of transcatheter aortic valve replacement.
T
ranscatheter aortic valve replacement (TAVR) has emerged as superior to medical therapy in prohibitive risk patients 1 and noninferior or superior to surgical aortic valve replacement in highand intermediate-risk patients. [2] [3] [4] [5] [6] [7] Women have accounted for >50% of patients enrolled in these clinical trials, yet there remain conflicting reports about the effect of sex on outcomes. Most individual trials and registries have failed to show a significant effect of sex on midterm survival. Leveraging greater statistical power, a meta-analysis encompassing 47 188 patients revealed a modestly lower 1-year mortality risk in women, albeit a paradoxically higher 30-day morbidity risk. 8 Adding to this complexity, women are typically older with higher predicted risk of mortality; however, they have fewer comorbidities and better systolic cardiac function.
Frailty is presumed to be more common in female patients, but the sex-specific prevalence and prognostic impact of frailty has not been systematically studied in the context of TAVR. Frailty has physical, cognitive, psychosocial dimensions, and these may be differentially expressed in women and men. Such differences would influence the delivery of targeted intervention for frailty. Because of a lower absolute muscle mass at baseline, women have lower reserves and are more vulnerable to progressive physical frailty after a surgical procedure. Thus, women may be at incrementally higher risk of deconditioning, disability, and death. This interaction was suggested in our prior work, where the adjusted odds ratio for the association between slow gait speed and postoperative major morbidity was substantially greater in women than men. 9 Thus, we sought to determine the sex-specific differences in the prevalence and prognostic impact of frailty among older adults undergoing TAVR. Additionally, we sought to compare the risk factors for short and midterm mortality and morbidity in women and men.
METHODS Study Design and Setting
A preplanned analysis of the FRAILTY-AVR study (Frailty Aortic Valve Replacement) was performed to analyze the sex-specific differences and determinants of outcomes after TAVR. The design of FRAILTY-AVR has been described in detail 10 ; briefly, this was a prospective cohort study conducted at 14 institutions in Canada, the United States, and France. Recruitment for the primary analysis took place between January 2012 and December 2015 and continued in an ongoing registry at selected institutions until the end of 2017. At the time of data analysis, 96% had reached and completed their 12-month follow-up assessment. The data that support the findings of this study may be made available from the corresponding author on reasonable request. The present article was prepared in agreement with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines 11 and complies with the Declaration of Helsinki. At each participating institution, the appointed ethics committee approved the research protocol.
Participants
Patients with aortic stenosis scheduled to undergo TAVR were eligible if they were 70 years of age or older and signed an informed consent form before participation. Exclusion criteria were emergency procedures, concomitant planned surgical procedures, clinical instability, severe neuropsychiatric impairment, or prohibitive language barrier. Before TAVR, patients were invited to complete a structured questionnaire and physical performance battery focused on frailty. Trained observers extracted clinical, imaging, and procedural data from medical records and contacted patients or their proxies by telephone at 6 and 12 months to administer a questionnaire focused on their recovery and vital status.
Assessment of Frailty
Frailty was classified using several scales; for the purposes of this analysis, 4 were retained to represent physical frailty and multidimensional frailty. The Essential Frailty Toolset (EFT) is scored 0 to 5 and consists of timed chair rises, cognitive impairment, anemia, and hypoalbuminemia. 10 The Columbia scale is scored 0 to 12 and consists of gait speed, handgrip strength, disability for activities of daily living, and hypoalbuminemia. 12 The Clinical Frailty Scale is scored 0 to 9 and consists of a composite judgment of mobility, comorbidity, and disability. 13 The Fried scale is scored 0 to 5 and consists of gait speed, handgrip strength, unintentional weight loss, exhaustion, and low physical activity.
14 The Short Physical Performance Battery is scored 0 to 12 and consists of timed chair rises, gait speed, and standing balance. 15 The latter 2 scales predominantly represent physical frailty.
Outcome Measures
The primary outcome was death from any cause within 12 months after the index TAVR procedure. Vital status was
WHAT IS KNOWN
• Frailty is associated with adverse outcomes in women and men undergoing transcatheter aortic valve replacement.
• Previous studies have reported discordant results on the effect of sex on outcomes, in part because they did not account for the potential interaction between sex and frailty.
WHAT THE STUDY ADDS
• Women have higher levels of physical but not cognitive frailty at baseline, which may be an impediment to functional recovery after transcatheter aortic valve replacement.
• Women with large implanted prostheses and those with pulmonary hypertension are at higher risk of short and midterm morbidity, respectively.
ascertained by a combination of medical records, death certificates, linkage to administrative data, and contact with the patients and their family members. The secondary outcome was a composite safety end point within 30 days after the index TAVR procedure, based on any of the following from the Second Valve Academic Research Consortium: death from any cause, major vascular complication, major bleed, stroke, acute kidney injury (stage 2 or 3), or reintervention for coronary obstruction, valve dysfunction, or other unplanned complication. Adverse events were adjudicated by local investigators and disagreements were resolved by consensus.
Statistical Analyses
Continuous variables were presented as mean±SD and compared using the Student t test. Categorical variables were presented as counts (proportions) and compared using the χ 2 test. Multivariable logistic regression models were stratified by sex and adjusted for age, frailty as measured by the EFT, disability as measured by the basic and instrumental activities of daily living, body mass index, atrial fibrillation, coronary artery disease, cerebrovascular disease, peripheral arterial disease, chronic lung disease, glomerular filtration rate, New York Heart Association class, left ventricular ejection fraction, mean aortic gradient, pulmonary hypertension (PH) as defined by a pulmonary arterial systolic pressure (PASP) ≥60 versus <60 mm Hg or not available, femoral versus nonfemoral access, and TAVR prosthesis size. Interaction between sex and each of these covariates was evaluated on the multiplicative scale. One of these covariates, PASP, was evaluated in its dichotomous and continuous format as a sensitivity analysis. Kaplan-Meier curves were generated to compare survival in women and men. Receiver operating characteristic curves were generated to compare the discrimination of the different frailty scales in women and men. Because this was an analysis of an existing cohort with a given sample size, formal sample size calculation was not performed. The proportion of patients with missing data for key covariates was ≤3% (Table in the Data Supplement). Study data were managed using REDCap electronic data capture tools hosted at the Lady Davis Institute's Centre for Clinical Epidemiology (Montreal, Quebec). Statistical analyses were performed using Stata v14 (College Station, TX).
RESULTS

Patient Cohort
The cohort consisted of 340 women and 419 men who underwent TAVR (Table 1 ). The number of included and excluded patients is shown in the flow diagram (Figure in the Data Supplement). Women were older than men (84.2 versus 82.8 years; P<0.001) and had higher Society of Thoracic Surgeons predicted risk of mortality (6.5% versus 5.8%; P=0.02). Women were more likely to have musculoskeletal comorbidities but less likely to have diabetes mellitus and atherosclerotic comorbidities. Women had smaller iliofemoral arteries, smaller left ventricular outflow tract dimensions, and smaller TAVR prostheses implanted. Echocardiographic analysis showed that they were more likely to manifest heart failure with preserved ejection fraction as evidenced by higher left ventricular ejection fraction, higher left ventricular mass index, higher left atrial volume index (Table 2) . PASP was similar in women and men, with 12% having documented PH ≥60 mm Hg.
Frailty Characteristics
Women were more likely to express physical frailty traits (such as slow chair rising, slow gait speed, and weak handgrip strength) but they were equally likely to express nonphysical frailty traits (such as cognitive impairment and depressed mood; Table 3 ). Accordingly, they had a higher prevalence of frailty when physical frailty scales were used (Short Physical Performance Battery, Fried) but not when multidomain frailty scales were used (EFT, Columbia, Clinical Frailty Scale). In aggregate, the prevalence of frailty ranged from 38% to 63% in women to 25% to 57% in men.
Association Between Sex and Outcomes
At 1 month, 88 out of 340 women (26%) and 91 out of 419 men (22%) had experienced a mortality or major morbidity after TAVR, as shown in Figure 1 . At 12 months, 63 out of 333 women (19%) and 69 out of 395 men (17%) had died. After adjusting for covariates, female sex was found to be a significant predictor of the 1-month composite (odds ratio [OR] 1.64; 95% CI, 1.04-2.60), but not 12-month mortality (OR, 1.30; 95% CI, 0.76-2.22). Kaplan-Meier survival curves stratified by sex are shown in Figure 2 (log-rank P=0.45). The composite end point was driven by major vascular complications and a trend for early deaths in women, who were more likely to require discharge to rehabilitation or convalescence facilities (37% versus 24%; P<0.001). Thereafter, 12 months post-TAVR, women were not more likely than men to experience progressive disability or death (46% versus 41%; P=0.21).
Multivariable Predictors of 1-Month Mortality or Major Morbidity Stratified by Sex
In women, larger prosthesis size was found to be independently associated with 1-month mortality or major morbidity (Table 4) . Women who received a prosthesis ≥29 mm, as compared to <29 mm, had a 2-fold increase in mortality or major morbidity (42% versus 22%, P=0.001), whereas no such difference was observed in men (23% versus 19%, P=0.37; Figure 3 ). There was a statistical trend towards interaction (P=0.16) between sex and prosthesis size analyzed as a dichotomous variable. Frailty, as measured by the EFT, was predictive of mortality or major morbidity in the entire cohort (OR, 1.27 per EFT point; 95% CI, 1.07-1.50), with the effect being slightly more pronounced in men as compared to women but without statistical evidence of interaction (P=0.48).
Multivariable Predictors of 12-Month Mortality Stratified by Sex
In women, 4 variables were found to be independently associated with 12-month mortality ( Values are mean±SD or n (%). LV indicates left ventricle; LVEF, LV ejection fraction; LVOT, LV outflow tract; PASP, pulmonary artery systolic pressure; and RV, right ventricle.
*LV hypertrophy was defined as an LV mass index >95 g/m 2 in women and >115 g/m 2 in men. ). In men, of these variables, only frailty was associated with mortality. Atrial fibrillation and GFR were statistically significant in men but not in women, although the odds ratios were similar in magnitude across sexes and there was no formal evidence of interaction. The only interaction that achieved statistical significance for 12-month mortality was female sex and PH (P=0.037). At 12 months, 16 out of 41 women with PH (39%) and 9 out of 44 men with PH (20%) had died. Kaplan-Meier survival curves stratified by sex and presence of PH are shown in Figure 4 (P<0.001 for comparison of women with PH versus other subgroups).
Discrimination of Frailty Scales
When the discriminatory value of each frailty scale for 12-month mortality was compared and adjusted for the Society of Thoracic Surgeons predicted risk of mortality, the EFT was found to have the highest area under the receiver operating characteristic curve in both sexes as shown in Table 6 . Physical frailty scales (Short Physical Performance Battery, Fried) had higher discriminatory value in women, whereas multidomain frailty scales (EFT, Columbia, Clinical Frailty Scale) had similar discriminatory value in women and men.
Sensitivity Analysis
When PASP was treated as a continuous variable (instead of a binary variable with a threshold of 60 mm Hg), each incremental mm Hg was found to be independently associated with a 3% increase in odds of 12-month mortality among women (OR, 1.03; 95% CI, 1.01-1.06), but not among men (OR, 0.99; 95% CI, 0.97-1.02). This interaction between female sex and continuous PASP achieved statistical significance (P=0.02).
DISCUSSION
The present study is the first, to our knowledge, to investigate the interplay between sex, frailty, comorbidities, and outcomes in older adults undergoing TAVR. The results of this study can be summarized as follows ( Figure 5 ).
1. Frailty is associated with adverse short and midterm outcomes in women and men undergoing TAVR. 2. Women have higher levels of physical frailty at baseline, which is associated with higher rates of short-term complications and deconditioning requiring rehabilitation. 3. The complication rate, particularly major vascular complications, is increased in women treated with large prostheses. 4. The mortality rate is exponentially increased in women with PH. 5. In the absence of PH, women and men have similar recovery of function and survival at 1 year. These results underscore the importance of assessing and optimizing frailty in women and men before TAVR and anticipating the greater rehabilitation needs of frail older women. Preprocedural planning, with attention to access route and prosthesis sizing, is important to avoid major complications in women. Lastly, careful consideration of PH is warranted for risk stratification in women owing to its strong association with midterm survival.
Our results are consistent with previous studies and a comprehensive meta-analysis showing decreased atherosclerotic comorbidities, increased 30-day complications, and similar or slightly decreased 1-year mortality in women compared with men undergoing TAVR. 8, [16] [17] [18] [19] [20] [21] Our results add to the current body of evidence by demonstrating that post-TAVR outcomes are mediated by key covariates in women and that their manifestations of frailty are different than in men. Although previous studies had limited data on frailty, our study prospectively measured frailty using several scales and demonstrated that physical frailty traits are more prevalent and impactful in women, whereas nonphysical frailty traits (including cognitive impairment and depression 22 ) are equally prevalent in both sexes. Thus, depending on the type of frailty scale used, women would be expected to have a burden of frailty that is greater than or equal to men.
In FRAILTY-AVR, 10 frailty was shown to be a major risk factor for death and disability after TAVR, with the EFT emerging as the most predictive frailty scale. This preplanned substudy builds on these findings by showing that the EFT is the most predictive scale across both sexes and that the expression of frailty traits is distinguishable in women and men. Women have higher rates of physical frailty and deconditioning, and accordingly, higher requirements for rehabilitation postprocedure. 23 After the (more challenging) early recovery phase, women regain a level of functioning and life expectancy on par with men. This mirrors the experi- Although global indices of frailty were similarly predictive in women and men, purely physical indices were more predictive in women. The mechanisms for such heightened sensitivity to physical frailty are not fully understood. One potential explanation is that women have physiologically lower absolute muscle mass and strength at baseline and, therefore, less muscle reserves to withstand perioperative periods of catabolic stress without incurring disability and downstream morbidity. This hypothesis is consistent with a previous study by our group, in which muscle mass measured on the preprocedural CT was an independent predictor of mortality in women but not in men after TAVR. 25 Beyond frailty, our analyses identified other risk factors for adverse outcomes in women undergoing TAVR. These risk factors are in line with previous studies (which did not explicitly differentiate between women and men), and they include PH, 10, 26 low body mass index, 10 large prosthesis size, and nonfemoral access route. 27 Interestingly, the detrimental impact of PH and large prosthesis size was magnified in women, with the former achieving statistical significance for interaction (when treated as a dichotomous state in the main analysis and as a continuous parameter in the sensitivity analysis) and the latter achieving a trend towards interaction.
Although the hemodynamic and prognostic implications of PH are well characterized, [28] [29] [30] less is known about the interaction between PH and sex. Our finding of effect-modification is remarkably consistent with that of Lindman et al 31 from the PARTNER I study (Placement of Aortic Transcatheter Valves), in which the prevalence of moderate or severe PH was 25%, and PH was associated with increased mortality in women but not men (interaction P=0.02) as in our study.
Plausible explanations for this now-replicated interaction deserve further discussion. Is PH less well tolerated by a women's right ventricle? This is unlikely, as our data showed a similar rate of right ventricular dysfunction in women and men with PH. Is PH less likely to improve after TAVR in women? This is uncertain because our data showed a similar rate of persistent PH in a subset of 440 patients with early post-TAVR echocardiograms; however, late echocardiograms were not available, and a study by Masri et al 29 showed that indicators of moderate-to-severe diastolic dysfunction were more common in women and were predictive of persistent PH post-TAVR. Is PH driven by a distinct pathophysiology in women? This seems to be likely, as a study by Thenappan et al 32 showed that women were predisposed to PH secondary to heart failure with preserved ejection fraction and that this subtype of PH was associated with worse outcomes. In another study by Hart et al 33 focusing on PH in patients with mitral stenosis, women were 5-fold more likely than men to have elevated transpulmonary gradients, suggesting adverse (and less reversible) pulmonary vascular remodeling. In our study, women were more likely to manifest heart failure with preserved ejection fraction, which is not unexpected given their propensity to concentric hypertrophic remodeling in response to pressure overload from aortic stenosis. 34 Procedural complications and vascular events were more frequently observed in women, and our data suggested that women treated with larger prostheses were especially vulnerable. The interplay between implanted prosthesis size and vascular complications seems to be, at least in part, related to the use of large sheath sizes in women who have smaller femoral artery diameters. Hayashida et al 35 found that the sheath-to-femoral artery ratio was highly predictive of major vascular complications, particularly when it was ≥1.05. In our cohort, the sheath-to-femoral artery ratio was ≥1.05 in 24% of women as compared to 11% of men (P<0.001). This issue may become less problematic with newer-generation balloon-expandable and self-expandable TAVR devices that feature low profile delivery systems.
Limitations
This study should be interpreted in light of the following limitations. Although efforts were made to screen and enroll consecutive patients, participation was not mandatory, and therefore the study population may not be generalizable at large. As previously shown, 10 there were no systematic differences between included and excluded patients that would lead us to suspect a troublesome selection bias; moreover, a similar proportion of women and men were included from the screened sample. Echocardiographic pulmonary arterial pressure could not be reliably assessed in 159 patients because of suboptimal tricuspid regurgitation jet tracing; when catheterization-based pulmonary arterial pressure was not available, these patients were imputed to have no significant PH (<60 mm Hg). This approach, commonly used in the echocardiographic literature, may misclassify certain patients, although the likelihood of significant PH (≥60 mm Hg) is low in patients with no tricuspid regurgitation and no secondary signs of PH. Finally, the intensity and duration of cardiac rehabilitation after TAVR was not captured and, therefore, could not be adjusted for in our 1-year mortality model.
Conclusions
While women and men alike have excellent outcomes after TAVR, the current study highlights clinically meaningful differences that should be considered to optimize their care. First, women tend to be more physically frail before TAVR and more deconditioned after TAVR, leading to the undesirable outcome of not being fit for discharge home. Prehabilitation interventions would seem to be beneficial in such patients to avoid this scenario. Second, women face a higher risk of short-term (vascular) complications, which may be partly reduced by carefully selecting a delivery system that is not oversized relative to the available arterial access. Third, women with PH represent a very high-risk subgroup, warranting attentive evaluation of PH for risk stratification and follow-up. Further research is needed to better understand the interaction between sex and PH and elucidate treatment strategies.
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